GLP-3 Retatrutide (2 x 24mg vials)
$220.00
Buy GLP-3 Retatrutide (2 x 24mg vials) to support your metabolic health. Each vial offers high purity and rigorous testing for optimal results. This peptide is designed for those looking to enhance their metabolic process effectively.
GLP-3 Retatrutide
Swipe right to view full table →
Save over 80%!
Product Format |
24mg vials |
Vial Size |
24mg |
Vial Capacity |
3 mL |
Box Combinations |
48mg, 120mg, 240mg, 480mg |
Cost per milligram |
$3.15 – $4.79 |
Multi-vial Purity |
99.76% |
Endotoxin Screening |
PASSED |
Heavy Metals Screening |
PASSED |
Purity Screening |
PASSED |
Independently Tested |
YES |
- 24mg Vials
- Peptide Partners Manufacturer ID: WF03
- Batch ID: RT202607
Research Studies
(for educational purposes only)
Study 1: Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
Authors: Wenzhuo Li, Qingtong Zhou, Zhaotong Cong, Qingning Yuan, Wenxin Li, Fenghui Zhao, H. Eric Xu, Li-Hua Zhao, Dehua Yang & Ming-Wei Wang
Source: https://www.nature.com/articles/s41421-024-00700-0
Scientific Findings
This study utilized cryo-electron microscopy to elucidate the structural basis of Retatrutide’s triple agonism at the GLP-1, GIP, and GCG receptors. The researchers determined the structures of Retatrutide in complex with each of the three receptors, revealing that the peptide adopts a single continuous helix. The triple agonism is achieved through a combination of conserved interactions and receptor-specific contacts within the transmembrane domain. The study identified key residues and structural features, such as the conformation of extracellular loop 1 (ECL1) in GIPR, that contribute to the differential binding and activation of the receptors. Mutagenesis and cAMP signaling assays confirmed the functional importance of these interactions, providing a molecular blueprint for Retatrutide’s potent and balanced activity.
Plain English Interpretation
Scientists have figured out how the new weight-loss drug, Retatrutide, works at a molecular level. This drug is unique because it can activate three different hormone receptors in the body that control appetite and metabolism. Using powerful microscopes, the researchers took detailed 3D pictures of Retatrutide as it was bound to each of these three receptors. They discovered that the drug uses a clever strategy of both sticking to parts that all three receptors have in common and also making specific connections with unique parts of each receptor. This allows it to effectively ‘talk’ to all three at once, leading to its powerful effects on weight loss and blood sugar control. Understanding this mechanism helps to explain why Retatrutide is so effective and can guide the development of even better medicines in the future.
Study 2: Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids
Authors: Yi Wen, Deven Lemen, Yanzhu Lin, Yan Q Chen, Ajit Regmi, William C Roell, Melissa K Thomas, Mark L Hartman, Tamer Coskun, Zvonko Milicevic, Axel Haupt, Giacomo Ruotolo, Robert J Konrad
Source: https://pubmed.ncbi.nlm.nih.gov/40726454/
Scientific Findings
This study investigated the effect of Retatrutide on circulating concentrations of the angiopoietin-like protein 3/8 complex (ANGPTL3/8) and its relationship with serum lipid levels. The study included both in vivo analysis from two phase 2 clinical trials and in vitro experiments using primary human hepatocytes. The in vitro component demonstrated that both glucagon and Retatrutide directly decreased ANGPTL3/8 secretion from hepatocytes, and this effect was blocked by a glucagon receptor (GCGR) antagonist. These findings suggest that the GCGR agonism of Retatrutide contributes to the reduction in circulating ANGPTL3/8, which in turn may lead to lower triglyceride and LDL-cholesterol levels.
Plain English Interpretation
Researchers explored how Retatrutide, a new drug for diabetes and obesity, helps lower bad fats in the blood. They found that Retatrutide reduces the levels of a protein complex called ANGPTL3/8, which is known to increase fats like triglycerides and LDL cholesterol. To understand how this happens, they conducted experiments on human liver cells in a lab dish. They discovered that Retatrutide directly acts on these cells to decrease the secretion of ANGPTL3/8. This suggests that part of Retatrutide’s effectiveness in improving cholesterol levels comes from its direct action on the liver, providing a clearer picture of how this promising new drug works.
Study 3: Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP
Authors: Xin Cui, Yueming Zhu, Lidan Zeng, Mengyuan Zhang, Amad Uddin, Theresa W Gillespie, Lauren E McCullough, Shaying Zhao, Mylin A Torres, Yong Wan
Source: https://pubmed.ncbi.nlm.nih.gov/39868848/
Scientific Findings
This study elucidates a molecular mechanism by which Retatrutide overcomes therapeutic resistance in obese triple-negative breast cancer (TNBC). The research identifies a dysfunctional EIF3H/YAP proteolytic axis as a key mediator between cancer-associated adipocytes and drug response. In vitro experiments demonstrated that cancer-associated adipocytes upregulate the hexosamine biosynthetic pathway (HBP), leading to O-GlcNAcylation and stabilization of the YAP protein. Retatrutide was found to inhibit the HBP, thereby preventing YAP O-GlcNAcylation and promoting its degradation. This, in turn, suppresses tumor growth and enhances chemotherapy efficacy. The study provides a detailed mechanistic insight into the interplay between metabolic reprogramming, protein stability, and drug response in the context of obesity and cancer.
Plain English Interpretation
Scientists have discovered how the weight-loss drug Retatrutide can also help treat a type of breast cancer that is more common in obese patients. They found that fat cells near the tumor can make the cancer cells resistant to treatment. These fat cells cause a change in the cancer cells’ metabolism, which leads to the buildup of a protein called YAP that helps the cancer grow. The researchers showed that Retatrutide can reverse this process. In lab experiments, Retatrutide blocked the metabolic changes caused by the fat cells and caused the YAP protein to be destroyed. This made the cancer cells more sensitive to chemotherapy. This research uncovers a new way that obesity affects cancer and suggests that drugs like Retatrutide could be used to improve cancer treatment in obese patients.
Storage:
All of our manufacturing partners produce peptides using the Lyophilization (Freeze Drying) process, ensuring products maintain stability for shipping and storage for 12+ months.
In lyophilized form, they are shelf-stable for many weeks. However, for long-term storage, it is recommended to store them in the freezer.
We often hear concerns about the standard “discard after 28 days of first use” disclaimer. Don’t worry, this has nothing to do with studies regarding the efficacy of specific peptides. 28 days is the FDA requirement for producers of multi-use vials to prove their bacteriostatic maintains efficacy. This minimum requirement becomes the de facto standard.
In our experience, if you use proper sterile procedures and refrigerated storage, you can continue sampling from the same reconstituted vial for 3+ months.
Third-party testing
Peptide Partners is committed to providing high-purity peptides at wholesale prices by frequently auditing its manufacturing partners using third-party laboratories. Independent analysis is vital to ensuring the quality and authenticity of your research peptides. Never trust a supplier that doesn’t submit to third-party testing. Never trust a certification that cannot be independently verified. All of the certificates that we provide can be validated on the third-party laboratory’s website.
Each product description contains a Manufacturer ID corresponding to the producer of that product. The table below contains the most recent third-party analyses for all manufacturers and peptides listed on Peptide Partners.
Current Purity certifications
|
Peptide |
Batch Id |
Manufacturer |
Date |
Purity |
Laboratory |
Double Validated |
|
|
Kisspeptin-10 |
KSS2607 |
VI32 |
2026-07-02 |
99.71% |
Kovera |
View File |
|
|
Reconstitution Solution |
BAC202606 |
WF03 |
2026-07-13 |
99.9% |
Kovera |
View File |
|
|
Retatrutide |
RTT2613 |
WF03 |
2026-07-02 |
99.77% |
Kovera |
View File |
|
|
PT-141 |
PT202605 |
VI32 |
2026-06-25 |
99.74% |
Kovera |
View File |
|
|
Tesamorelin |
TES202607 |
WF03 |
2026-06-19 |
99.80% |
TrustPointe |
View File |
|
|
KPV |
KV202606 |
WF03 |
2026-06-12 |
99.36% |
TrustPointe |
Yes |
View File |
|
BPC-157 |
BC202607 |
WF03 |
2026-06-12 |
99.82% |
TrustPointe |
Yes |
View File |
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-12 |
99.98% |
TrustPointe |
Yes |
View File |
|
Semaglutide |
SM202607 |
VI32 |
2026-06-12 |
99.96% |
TrustPointe |
Yes |
View File |
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-12 |
99.36% |
Kovera |
Yes |
View File |
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-10 |
99.88% |
TrustPointe |
Yes |
View File |
|
BPC-157 |
BC202607 |
WF03 |
2026-06-10 |
99.74% |
Kovera |
Yes |
View File |
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-10 |
99.71% |
Kovera |
Yes |
View File |
|
Retatrutide |
RT202607 |
WF03 |
2026-06-09 |
99.76% |
Kovera |
View File |
|
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-09 |
99.55% |
Kovera |
Yes |
View File |
|
Semaglutide |
SM202607 |
VI32 |
2026-06-10 |
99.68% |
Kovera |
Yes |
View File |
|
KPV |
KV202606 |
WF03 |
2026-06-10 |
99.70% |
Kovera |
Yes |
View File |
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-10 |
99.34% |
TrustPointe |
Yes |
View File |
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-09 |
99.65% |
Kovera |
Yes |
View File |
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-09 |
99.90% |
Kovera |
Yes |
View File |
|
NAD+ |
NDB202606 |
WF03 |
2026-05-28 |
99.55% |
TrustPointe |
View File |
|
|
GHK-Cu |
CU202605 |
WF03 |
2026-05-13 |
99.67% |
TrustPointe |
View File |
|
|
Epithalon |
ET202604 |
WF03 |
2026-05-13 |
99.86% |
Kovera |
View File |
|
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-13 |
99.78% |
Kovera |
Yes |
View File |
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-29 |
99.53% |
Chromate |
Yes |
View File |
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-11 |
99.22% |
TrustPointe |
Yes |
View File |
|
MOTS-c |
MC202605 |
WF03 |
2026-06-08 |
99.98% |
TrustPointe |
View File |
|
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-08 |
99.94% |
TrustPointe |
Yes |
View File |
|
TB-500 (TB4) |
TB202605 |
WF03 |
2026-05-28 |
99.76% |
TrustPointe |
View File |
|
|
Tesamorelin |
TES202605 |
WF03 |
2026-05-28 |
99.81% |
TrustPointe |
View File |
|
|
Retatrutide |
RT202605 |
WF03 |
2026-05-27 |
99.75% |
TrustPointe |
View File |
|
|
Reconstitution Solution |
BAC202602 |
VI32 |
2026-05-14 |
99.90% |
Kovera |
View File |
|
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-14 |
99.93% |
TrustPointe |
View File |
|
|
Cagrilintide |
CG202607 |
WF03 |
2026-05-14 |
99.74% |
TrustPointe |
View File |
|
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-05-14 |
99.73% |
TrustPointe |
Yes |
View File |
|
GHK-Cu |
CU202604 |
WF03 |
2026-05-14 |
99.74% |
TrustPointe |
Yes |
View File |
|
BPC-157 |
BC202604 |
VI32 |
2026-05-13 |
99.72% |
TrustPointe |
Yes |
View File |
|
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin |
CIT202604 |
WF03 |
2026-05-07 |
99.82% |
Kovera |
View File |
|
|
Tesamorelin |
TES202604 |
WF03 |
2026-04-21 |
99.85% |
Kovera |
View File |
|
|
DSIP |
DS202605 |
WF03 |
2026-05-07 |
99.81% |
Kovera |
View File |
|
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-04-21 |
99.90% |
Kovera |
Yes |
View File |
|
KLOW Blend |
KW202604 |
WF03 |
2026-04-21 |
99.86% |
Kovera |
View File |
|
|
AOD-9604 |
AO202605 |
WF03 |
2026-04-20 |
99.93% |
Kovera |
View File |
|
|
Cagrilintide |
CG202603 |
VI32 |
2026-04-14 |
99.90% |
Kovera |
View File |
|
|
MOTS-c |
MC202603 |
VI32 |
2026-04-04 |
99.96% |
Kovera |
View File |
|
|
Retatrutide |
RT202604 |
WF03 |
2026-04-16 |
99.54% |
TrustPointe |
View File |
|
|
Sermorelin |
SER202601 |
VI32 |
2026-04-01 |
99.94% |
Kovera |
View File |
|
|
Pinealon |
PN202603 |
WF03 |
2026-04-01 |
99.96% |
Kovera |
View File |
|
|
GHK-Cu |
CU202604 |
WF03 |
2026-04-03 |
99.93% |
Kovera |
Yes |
View File |
|
SS-31 |
SS202601 |
WF03 |
2026-04-03 |
99.82% |
TrustPointe |
View File |
|
|
Semax |
SX202603 |
WF03 |
2026-03-31 |
99.91% |
Kovera |
View File |
|
|
Retatrutide |
RT202603 |
WF03 |
2026-03-30 |
99.40% |
TrustPointe |
View File |
|
|
GLOW Blend |
GW202603 |
WF03 |
2026-03-25 |
99.88% |
Kovera |
View File |
|
|
Tirzepatide |
TZ202603 |
VI32 |
2026-03-27 |
99.89% |
TrustPointe |
View File |
|
|
BPC-157/TB-500 |
BB202604 |
WF03 |
2026-03-27 |
99.63% |
TrustPointe |
View File |
|
|
Tesamorelin |
TES202603 |
WF03 |
2026-03-25 |
99.52% |
TrustPointe |
View File |
|
|
BPC-157 |
BC202604 |
VI32 |
2026-03-18 |
99.60% |
TrustPointe |
Yes |
View File |
|
Ipamorelin/CJC-1295 (No DAC) |
CJIP202602 |
WF03 |
2026-02-27 |
99.92% |
TrustPointe |
View File |
|
|
Thymosin Alpha-1 |
TA202602 |
WF03 |
2026-02-25 |
99.95% |
Kovera |
View File |
|
|
KLOW |
KW202602 |
WF03 |
2026-03-01 |
99.86% |
Chromate |
View File |
|
|
NAD+ |
NDB202601 |
VI32 |
2026-02-07 |
99.92% |
Kovera |
View File |
|
|
SS-31 |
SS202602 |
WF03 |
2026-02-08 |
99.68% |
Chromate |
View File |
|
|
MOTS-c |
MC202602 |
WF03 |
2026-02-09 |
99.41% |
Chromate |
View File |
|
|
Selank |
SEK202601 |
VI32 |
2026-01-29 |
99.94% |
Chromate |
View File |
|
|
Unbuffered NAD+ |
NDU202601 |
MZ21 |
2026-01-20 |
99.85% |
Chromate |
View File |
|
|
KPV |
KV202601 |
VI32 |
2026-01-20 |
99.90% |
Chromate |
View File |
|
|
Ipamorelin |
IP202601 |
WF03 |
2026-01-14 |
99.92% |
TrustPointe |
View File |
|
|
TB500 (TB4) |
TB202601 |
WF03 |
2026-01-14 |
99.86% |
TrustPointe |
View File |
|
|
Retatrutide |
RT202602 |
WF03 |
2026-01-13 |
99.63% |
TrustPointe |
View File |
|
|
PT-141 |
PT202512 |
VI32 |
2026-01-12 |
99.89% |
BioRegen |
View File |
|
|
Semaglutide |
SM202601 |
MZ21 |
2026-01-10 |
99.70% |
TrustPointe |
View File |
|
|
Cagrilintide |
CAG202601 |
MZ21 |
2026-01-10 |
99.33% |
TrustPointe |
View File |
|
|
Tesamorelin |
TES202601 |
WF03 |
2025-12-29 |
99.71% |
TrustPointe |
View File |
|
|
BPC-157 |
BP202512 |
WF03 |
2025-12-29 |
99.46% |
TrustPointe |
View File |
|
|
BPC-157/TB-500 |
BB202512 |
WF03 |
2025-12-29 |
99.64% |
TrustPointe |
View File |
|
|
GHK-Cu |
GK202512 |
SH07 |
2025-12-19 |
99.79% |
BioRegen |
View File |
|
|
MOTS-c |
MC202512 |
WF03 |
2025-12-22 |
99.89% |
BioRegen |
View File |
|
|
Retatrutide |
RP260130 |
VI32 |
2025-12-22 |
99.72% |
TrustPointe |
View File |
|
|
SS-31 |
SS202512 |
WF03 |
2025-12-19 |
99.70% |
TrustPointe |
View File |
|
|
Retatrutide |
RP202601 |
DF05 |
2025-12-22 |
99.63% |
TrustPointe |
View File |
|
|
Ipamorelin/CJC-1295 (No DAC) |
CJIP202512 |
WF03 |
2025-12-09 |
99.80% |
TrustPointe |
View File |
|
|
Retatrutide |
RP202511 |
DF05 |
2025-12-19 |
99.73% |
TrustPointe |
View File |
|
|
Retatrutide |
RP20251020 |
DF05 |
2025-11-10 |
99.33% |
TrustPointe |
View File |
|
|
Retatrutide |
RP20251001 |
DF05 |
2025-10-13 |
99.86% |
TrustPointe |
View File |
|
|
Tirzepatide |
TZ20250915 |
DF05 |
2025-10-03 |
99.74% |
TrustPointe |
View File |
|
|
Retatrutide |
RP20250929 |
VI32 |
2025-10-03 |
99.47% |
TrustPointe |
View File |
|
|
Humanin |
HP20250805 |
WF03 |
2025-09-19 |
99.92% |
BioRegen |
View File |
|
|
MOTS-c |
YC20250807 |
WF03 |
2025-09-19 |
99.87% |
BioRegen |
View File |
|
|
DSIP |
DS20250820 |
SH07 |
2025-09-19 |
99.88% |
BioRegen |
View File |
|
|
SS-31 |
SY20250806 |
WF03 |
2025-09-19 |
99.70% |
BioRegen |
View File |
|
|
CJC/Ipamorelin |
CI20250805 |
WF03 |
2025-09-11 |
99.84% |
TrustPointe |
View File |
|
|
BPC-157 |
BP20250808 |
WF03 |
2025-09-05 |
99.99% |
TrustPointe |
View File |
|
|
Sermorelin |
SM20250723 |
WF03 |
2025-08-27 |
99.84% |
BioRegen |
View File |
|
|
Tesamorelin |
TS20250722 |
WF03 |
2025-08-22 |
99.10% |
TrustPointe |
View File |
|
|
CJC-1295 ND |
CJ20250724 |
WF03 |
2025-08-20 |
99.43% |
TrustPointe |
View File |
|
|
Semaglutide |
SM20250801 |
EJ12 |
2025-08-20 |
99.34% |
TrustPointe |
View File |
|
|
Ipamorelin |
IP20250721 |
WF03 |
2025-08-15 |
99.64% |
TrustPointe |
View File |
|
|
GHK-Cu |
CU20250717 |
SH07 |
2025-08-09 |
99.73% |
BioRegen |
View File |
|
|
Tirzepatide |
TZ20250730 |
EJ12 |
2025-08-08 |
99.41% |
TrustPointe |
View File |
|
|
NAD+ |
ND20250503 |
SH07 |
2025-07-31 |
99.76% |
BioRegen |
View File |
|
|
VIP |
VP20250511 |
SH07 |
2025-07-31 |
99.42% |
BioRegen |
View File |
|
|
Retatrutide |
CD20250708 |
SH07 |
2025-07-25 |
99.42% |
TrustPointe |
View File |
|
|
BPC/TB500 |
BB20250630 |
SH07 |
2025-07-17 |
99.52% |
TrustPointe |
View File |
|
|
TB500 (TB4) |
TB20250614 |
SH07 |
2025-07-17 |
99.68% |
TrustPointe |
View File |
Current Endotoxin Certifications
|
Peptide |
Batch Id |
Manufacturer |
Date |
USP Conformation |
Laboratory |
|
|
Kisspeptin-10 |
KSS2607 |
VI32 |
2026-06-30 |
Conforms |
Kovera |
View File |
|
Reconstitution Solution |
BAC202606 |
WF03 |
2026-07-13 |
Conforms |
Kovera |
View File |
|
Retatrutide |
RTT2613 |
WF03 |
2026-06-30 |
Conforms |
Kovera |
View File |
|
Tesamorelin |
TES202607 |
WF03 |
2026-06-22 |
Conforms |
TrustPointe |
View File |
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-15 |
Conforms |
TrustPointe |
View File |
|
PT-141 |
PT202605 |
VI32 |
2026-06-12 |
Conforms |
Kovera |
View File |
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-12 |
Conforms |
Kovera |
View File |
|
MOTS-c |
MC202605 |
WF03 |
2026-06-11 |
Conforms |
TrustPointe |
View File |
|
Semaglutide |
SM202607 |
VI32 |
2026-06-10 |
Conforms |
Kovera |
View File |
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-10 |
Conforms |
Kovera |
View File |
|
KPV |
KV202606 |
WF03 |
2026-06-10 |
Conforms |
Kovera |
View File |
|
BPC-157 |
BC202607 |
WF03 |
2026-06-10 |
Conforms |
Kovera |
View File |
|
Retatrutide |
RT202607 |
WF03 |
2026-06-09 |
Conforms |
Kovera |
View File |
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-09 |
Conforms |
Kovera |
View File |
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-09 |
Conforms |
Kovera |
View File |
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-11 |
Conforms |
TrustPointe |
View File |
|
Epithalon |
ET202604 |
WF03 |
2026-05-13 |
Conforms |
Kovera |
View File |
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-13 |
Conforms |
Kovera |
View File |
|
NAD+ |
NDB202606 |
WF03 |
2026-05-28 |
Conforms |
TrustPointe |
View File |
|
TB-500 (TB4) |
TB202605 |
WF03 |
2026-05-28 |
Conforms |
TrustPointe |
View File |
|
Tesamorelin |
TES202605 |
WF03 |
2026-05-28 |
Conforms |
TrustPointe |
View File |
|
Retatrutide |
RT202605 |
WF03 |
2026-05-27 |
Conforms |
TrustPointe |
View File |
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-14 |
Conforms |
TrustPointe |
View File |
|
GHK-Cu |
CU202605 |
WF03 |
2026-05-18 |
Conforms |
TrustPointe |
View File |
|
Cagrilintide |
CG202607 |
WF03 |
2026-05-18 |
Conforms |
TrustPointe |
View File |
|
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin |
CIT202604 |
WF03 |
2026-05-07 |
Conforms |
Kovera |
View File |
|
Tesamorelin |
TES202604 |
WF03 |
2026-04-21 |
Conforms |
Kovera |
View File |
|
DSIP |
DS202605 |
WF03 |
2026-05-07 |
Conforms |
Kovera |
View File |
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-04-21 |
Conforms |
Kovera |
View File |
|
KLOW Blend |
KW202604 |
WF03 |
2026-04-21 |
Conforms |
Kovera |
View File |
|
AOD-9604 |
AO202605 |
WF03 |
2026-04-20 |
Conforms |
Kovera |
View File |
|
Retatrutide |
RT202604 |
WF03 |
2026-04-16 |
Conforms |
TrustPointe |
View File |
|
MOTS-c |
MC202603 |
VI32 |
2026-04-04 |
Conforms |
Kovera |
View File |
|
Pinealon |
PN202603 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
View File |
|
Cagrilintide |
CG202603 |
VI32 |
2026-04-14 |
Conforms |
Kovera |
View File |
|
Sermorelin |
SER202601 |
VI32 |
2026-04-01 |
Conforms |
Kovera |
View File |
|
GHK-Cu |
CU202604 |
WF03 |
2026-04-03 |
Conforms |
Kovera |
View File |
|
SS-31 |
SS202601 |
WF03 |
2026-04-03 |
Conforms |
TrustPointe |
View File |
|
Semax |
SX202603 |
WF03 |
2026-03-31 |
Conforms |
Kovera |
View File |
|
Retatrutide |
RT202603 |
WF03 |
2026-03-30 |
Conforms |
TrustPointe |
View File |
|
GLOW Blend |
GW202603 |
WF03 |
2026-03-25 |
Conforms |
Kovera |
View File |
|
Tirzepatide |
TZ202603 |
VI32 |
2026-03-27 |
Conforms |
TrustPointe |
View File |
|
BPC-157/TB-500 |
BB202604 |
WF03 |
2026-03-26 |
Conforms |
TrustPointe |
View File |
|
Tesamorelin |
TES202603 |
WF03 |
2026-03-25 |
Conforms |
TrustPointe |
View File |
|
SS-31 |
SS202602 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
View File |
|
CJC-1295 ND/Ipamorelin |
CJIP202602 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
View File |
|
KLOW Blend |
KW202602 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
View File |
|
BPC-157 |
BC202604 |
WF03 |
2026-03-17 |
Conforms |
Kovera |
View File |
|
Thymosin Alpha-1 |
TA202601 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
View File |
|
MOTS-c |
MC202602 |
WF03 |
2026-02-08 |
Conforms |
Kovera |
View File |
|
NAD+ |
NDB202601 |
VI32 |
2026-02-08 |
Conforms |
Kovera |
View File |
|
Unbuffered NAD+ |
NDU202601 |
MZ21 |
2026-01-28 |
Conforms |
TrustPointe |
View File |
|
KPV |
KV202601 |
VI32 |
2026-01-28 |
Conforms |
TrustPointe |
View File |
|
Ipamorelin |
IP202601 |
WF03 |
2026-01-13 |
Conforms |
TrustPointe |
View File |
|
TB500 |
TB202601 |
WF03 |
2026-01-13 |
Conforms |
TrustPointe |
View File |
|
Retatrutide |
RT202602 |
WF03 |
2026-01-13 |
Conforms |
TrustPointe |
View File |
|
PT-141 |
PT202512 |
VI32 |
2026-01-07 |
Conforms |
BioRegen |
View File |
|
Semaglutide |
SM202601 |
MZ21 |
2026-01-10 |
Conforms |
TrustPointe |
View File |
|
Cagrilintide |
CAG202601 |
MZ21 |
2026-01-10 |
Conforms |
TrustPointe |
View File |
|
Tesamorelin |
TES202601 |
WF03 |
2026-01-06 |
Conforms |
TrustPointe |
View File |
|
BPC-157 |
BP202512 |
WF03 |
2025-12-30 |
Conforms |
TrustPointe |
View File |
|
BPC-157/TB-500 |
BB202512 |
WF03 |
2025-12-30 |
Conforms |
TrustPointe |
View File |
|
Retatrutide |
RP260130 |
DF05 |
2025-12-22 |
Conforms |
TrustPointe |
View File |
|
SS-31 |
SS202512 |
WF03 |
2025-12-19 |
Conforms |
TrustPointe |
View File |
|
Retatrutide |
RP202601 |
DF05 |
2025-12-22 |
Conforms |
TrustPointe |
View File |
|
Ipamorelin/CJC-1295 (No DAC) |
CJIP202512 |
WF03 |
2025-12-08 |
Conforms |
TrustPointe |
View File |
|
Retatrutide |
RP202511 |
DF05 |
2025-11-10 |
Conforms |
TrustPointe |
View File |
|
Retatrutide |
RP20251020 |
DF05 |
2025-11-10 |
Conforms |
TrustPointe |
View File |
|
Retatrutide |
RP20251001 |
DF05 |
2025-10-13 |
Conforms |
TrustPointe |
View File |
|
Tirzepatide |
TZ20250915 |
DF05 |
2025-10-03 |
Conforms |
TrustPointe |
View File |
|
Retatrutide |
RP20250929 |
VI32 |
2025-10-03 |
Conforms |
TrustPointe |
View File |
|
Humanin |
HP20250805 |
WF03 |
2025-09-19 |
Conforms |
BioRegen |
View File |
|
MOTS-c |
YC20250807 |
WF03 |
2025-09-19 |
Conforms |
BioRegen |
View File |
|
DSIP |
DS20250820 |
SH07 |
2025-09-19 |
Conforms |
BioRegen |
View File |
|
SS-31 |
SY20250806 |
WF03 |
2025-09-19 |
Conforms |
BioRegen |
View File |
|
CJC/Ipamorelin |
CI20250805 |
WF03 |
2025-09-03 |
Conforms |
TrustPointe |
View File |
|
BPC-157 |
BP20250808 |
WF03 |
2025-09-03 |
Conforms |
TrustPointe |
View File |
|
Bacteriostatic Water |
BAC20250807 |
SH07 |
2025-08-27 |
Conforms |
BioRegen |
View File |
|
Tesamorelin |
TS20250722 |
WF03 |
2025-08-20 |
Conforms |
TrustPointe |
View File |
|
CJC-1295 ND |
CJ20250724 |
WF03 |
2025-08-20 |
Conforms |
TrustPointe |
View File |
|
Sermorelin |
SM20250723 |
WF03 |
2025-08-20 |
Conforms |
TrustPointe |
View File |
|
Semaglutide |
SM20250801 |
EJ12 |
2025-08-20 |
Conforms |
TrustPointe |
View File |
|
Ipamorelin |
IP20250721 |
WF03 |
2025-08-11 |
Conforms |
TrustPointe |
View File |
|
GHK-Cu |
CU20250717 |
SH07 |
2025-08-08 |
Conforms |
TrustPointe |
View File |
|
Tirzepatide |
TZ20250730 |
EJ12 |
2025-08-04 |
Conforms |
TrustPointe |
View File |
|
NAD+ |
ND20250503 |
SH07 |
2025-07-29 |
Conforms |
TrustPointe |
View File |
|
VIP |
VP20250511 |
SH07 |
2025-07-29 |
Conforms |
TrustPointe |
View File |
|
Retatrutide |
CD20250708 |
SH07 |
2025-07-24 |
Conforms |
TrustPointe |
View File |
|
BPC/TB500 |
BB20250630 |
SH07 |
2025-07-17 |
Conforms |
TrustPointe |
View File |
|
TB500 (TB4) |
TB20250614 |
SH07 |
2025-07-17 |
Conforms |
TrustPointe |
View File |
Current Heavy Metal Certifications
|
Peptide |
Batch Id |
Manufacturer |
Date |
Class 1 USP |
Full USP |
Laboratory |
|
|
Kisspeptin-10 |
KSS2607 |
VI32 |
2026-07-01 |
Conforms |
Kovera |
View File |
|
|
Retatrutide |
RTT2613 |
WF03 |
2026-07-01 |
Conforms |
Kovera |
View File |
|
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-26 |
Conforms |
TrustPointe |
View File |
|
|
KPV |
KV202606 |
WF03 |
2026-06-26 |
Conforms |
TrustPointe |
View File |
|
|
BPC-157 |
BC202607 |
WF03 |
2026-06-26 |
Conforms |
TrustPointe |
View File |
|
|
Tesamorelin |
TES202607 |
WF03 |
2026-06-26 |
Conforms |
TrustPointe |
View File |
|
|
Semaglutide |
SM202607 |
VI32 |
2026-06-25 |
Conforms |
TrustPointe |
View File |
|
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
View File |
|
|
Retatrutide |
RT202607 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
View File |
|
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
View File |
|
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
View File |
|
|
MOTS-c |
MC202605 |
WF03 |
2026-06-25 |
Conforms |
TrustPointe |
View File |
|
|
PT-141 |
PT202605 |
VI32 |
2026-06-13 |
Conforms |
Kovera |
View File |
|
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-12 |
Conforms |
Kovera |
View File |
|
|
Semaglutide |
SM202607 |
VI32 |
2026-06-11 |
Conforms |
Kovera |
View File |
|
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-11 |
Conforms |
Kovera |
View File |
|
|
KPV |
KV202606 |
WF03 |
2026-06-11 |
Conforms |
Kovera |
View File |
|
|
BPC-157 |
BC202607 |
WF03 |
2026-06-11 |
Conforms |
Kovera |
View File |
|
|
Retatrutide |
RT202607 |
WF03 |
2026-06-11 |
Conforms |
Kovera |
View File |
|
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-10 |
Conforms |
Kovera |
View File |
|
|
Epithalon |
ET202604 |
WF03 |
2026-05-14 |
Conforms |
Kovera |
View File |
|
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-14 |
Conforms |
Kovera |
View File |
|
|
NAD+ |
NDB202606 |
WF03 |
2026-06-05 |
Conforms |
TrustPointe |
View File |
|
|
Tesamorelin |
TES202605 |
WF03 |
2026-06-05 |
Conforms |
TrustPointe |
View File |
|
|
Retatrutide |
RT202605 |
WF03 |
2026-06-05 |
Conforms |
TrustPointe |
View File |
|
|
TB-500 |
TB202605 |
WF03 |
2026-06-05 |
Conforms |
TrustPointe |
View File |
|
|
GHK-Cu |
CU202605 |
WF03 |
2026-05-26 |
Conforms |
TrustPointe |
View File |
|
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-26 |
Conforms |
TrustPointe |
View File |
|
|
Cagrilintide |
CG202607 |
WF03 |
2026-05-26 |
Conforms |
TrustPointe |
View File |
|
|
SS-31 |
SS202602 |
WF03 |
2026-05-24 |
Conforms |
TrustPointe |
View File |
|
|
AOD-9604 |
AO202605 |
WF03 |
2026-05-24 |
Conforms |
TrustPointe |
View File |
|
|
GLOW Blend |
GW202603 |
WF03 |
2026-05-24 |
Conforms |
TrustPointe |
View File |
|
|
KLOW Blend |
KW202602 |
WF03 |
2026-05-24 |
Conforms |
TrustPointe |
View File |
|
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-16 |
Conforms |
Kovera |
View File |
|
|
Cagrilintide |
CG202607 |
WF03 |
2026-05-16 |
Conforms |
Kovera |
View File |
|
|
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin |
CIT202604 |
WF03 |
2026-04-26 |
Conforms |
Kovera |
View File |
|
|
Tesamorelin |
TES202604 |
WF03 |
2026-04-22 |
Conforms |
Kovera |
View File |
|
|
Pinealon |
PN202603 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
View File |
|
|
Semax |
SX202603 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
View File |
|
|
MOTS-c |
MC202602 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
View File |
|
|
Cagrilintide |
CG202603 |
VI32 |
2026-05-05 |
Conforms |
TrustPointe |
View File |
|
|
SS-31 |
SS202601 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
View File |
|
|
CJC-1295 ND/Ipamorelin |
CJIP202602 |
WF03 |
2026-05-05 |
Conforms |
TrustPointe |
View File |
|
|
DSIP |
DS202605 |
WF03 |
2026-04-24 |
Conforms |
Kovera |
View File |
|
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-04-21 |
Conforms |
Kovera |
View File |
|
|
KLOW Blend |
KW202604 |
WF03 |
2026-04-21 |
Conforms |
Kovera |
View File |
|
|
Retatrutide |
RT202604 |
WF03 |
2026-04-22 |
Conforms |
Kovera |
View File |
|
|
AOD-9604 |
AO202605 |
WF03 |
2026-04-20 |
Conforms |
Kovera |
View File |
|
|
SS-31 |
SS202601 |
WF03 |
2026-04-02 |
Conforms |
Kovera |
View File |
|
|
BPC-157/TB-500 |
BB202604 |
WF03 |
2026-04-03 |
Conforms |
TrustPointe |
View File |
|
|
Cagrilintide |
CG202603 |
VI32 |
2026-03-31 |
Conforms |
Kovera |
View File |
|
|
Pinealon |
PN202603 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
View File |
|
|
GLOW Blend |
GW202603 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
View File |
|
|
KLOW Blend |
KW202602 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
View File |
|
|
CJC-1295 ND/Ipamorelin |
CJIP202602 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
View File |
|
|
SS-31 |
SS202602 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
View File |
|
|
MOTS-c |
MC202602 |
WF03 |
2026-04-01 |
Conforms |
Kovera |
View File |
|
|
Tesamorelin |
TES202603 |
WF03 |
2026-04-03 |
Conforms |
TrustPointe |
View File |
|
|
Sermorelin |
SER202601 |
VI32 |
2026-03-29 |
Conforms |
Kovera |
View File |
|
|
MOTS-c |
MC202603 |
VI32 |
2026-04-01 |
Conforms |
Kovera |
View File |
|
|
Retatrutide |
RT202603 |
WF03 |
2026-04-03 |
Conforms |
TrustPointe |
View File |
|
|
Semax |
SX202603 |
WF03 |
2026-03-31 |
Conforms |
Kovera |
View File |
|
|
GLOW Blend |
GW202603 |
WF03 |
2026-03-26 |
Conforms |
Kovera |
View File |
|
|
Tirzepatide |
TZ202603 |
VI32 |
2026-03-26 |
Conforms |
Kovera |
View File |
|
|
BPC-157 |
BC202604 |
WF03 |
2026-03-17 |
Conforms |
Kovera |
View File |
|
|
Thymosin Alpha-1 |
TA202602 |
WF03 |
2026-02-25 |
Conforms |
Kovera |
View File |
|
|
NAD+ |
NDB202601 |
VI32 |
2026-02-08 |
Conforms |
Kovera |
View File |
|
|
Ipamorelin |
IP202601 |
WF03 |
2026-01-26 |
Conforms |
TrustPointe |
View File |
|
|
TB500 |
TB202601 |
WF03 |
2026-01-26 |
Conforms |
TrustPointe |
View File |
|
|
Retatrutide |
RT202602 |
WF03 |
2026-01-26 |
Conforms |
TrustPointe |
View File |
|
|
Semaglutide |
SM202601 |
MZ21 |
2026-01-19 |
Conforms |
TrustPointe |
View File |
|
|
Cagrilintide |
CAG202601 |
MZ21 |
2026-01-19 |
Conforms |
TrustPointe |
View File |
|
|
Tesamorelin |
TES202601 |
WF03 |
2026-01-19 |
Conforms |
TrustPointe |
View File |
|
|
BPC-157 |
BP202512 |
WF03 |
2026-01-08 |
Conforms |
TrustPointe |
View File |
|
|
BPC-157/TB-500 |
BB202512 |
WF03 |
2026-01-08 |
Conforms |
TrustPointe |
View File |
|
|
Tirzepatide |
TZ20250915 |
DF05 |
2025-12-03 |
Conforms |
TrustPointe |
View File |
|
|
TB500 (TB4) |
TB20250614 |
SH07 |
2025-11-24 |
Conforms |
TrustPointe |
View File |
|
|
BPC-157 |
BP20250808 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
View File |
|
|
BPC/TB500 |
BB20250630 |
SH07 |
2025-11-12 |
Conforms |
TrustPointe |
View File |
|
|
CJC-1295 ND |
CJ20250724 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
View File |
|
|
GHK-Cu |
CU20250717 |
SH07 |
2025-11-12 |
Conforms |
TrustPointe |
View File |
|
|
Ipamorelin |
IP20250721 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
View File |
|
|
Retatrutide |
RP20251020 |
DF05 |
2025-11-12 |
Conforms |
TrustPointe |
View File |
|
|
Sermorelin |
SM20250723 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
View File |
|
|
SS-31 |
SY20250806 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
View File |
|
|
TB500 (TB4) |
TB20250614 |
SH07 |
2025-11-12 |
Conforms |
TrustPointe |
View File |
|
|
Tesamorelin |
TS20250722 |
WF03 |
2025-11-12 |
Conforms |
TrustPointe |
View File |
|
|
Tirzepatide |
TZ20250730 |
EJ12 |
2025-11-12 |
Conforms |
TrustPointe |
View File |
Current Sterility Certifications
|
Product |
Batch Id |
Manufacturer |
Date |
USP Pass/Fail |
Rapid Pass/Fail |
Laboratory |
File |
|
Kisspeptin-10 |
KSS2607 |
VI32 |
2026-06-30 |
Pass |
Kovera |
View File |
|
|
Retatrutide |
RTT2613 |
WF03 |
2026-06-30 |
Pass |
Kovera |
View File |
|
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-26 |
Pass |
TrustPointe |
View File |
|
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-26 |
Pass |
TrustPointe |
View File |
|
|
Reconstitution Solution |
BAC202603 |
VI32 |
2026-06-26 |
Pass |
TrustPointe |
View File |
|
|
MOTS-c |
MC202605 |
WF03 |
2026-06-23 |
Pass |
TrustPointe |
View File |
|
|
NAD+ |
NDB202606 |
WF03 |
2026-06-15 |
Pass |
TrustPointe |
View File |
|
|
Tesamorelin |
TES202605 |
WF03 |
2026-06-15 |
Pass |
TrustPointe |
View File |
|
|
Retatrutide |
RTT202606 |
WF03 |
2026-06-12 |
Pass |
Kovera |
View File |
|
|
PT-141 |
PT202605 |
VI32 |
2026-06-12 |
Pass |
Kovera |
View File |
|
|
Semaglutide |
SM202607 |
VI32 |
2026-06-10 |
Pass |
Kovera |
View File |
|
|
Ipamorelin |
IP202606 |
WF03 |
2026-06-10 |
Pass |
Kovera |
View File |
|
|
KPV |
KV202606 |
WF03 |
2026-06-10 |
Pass |
Kovera |
View File |
|
|
BPC-157 |
BC202607 |
WF03 |
2026-06-10 |
Pass |
Kovera |
View File |
|
|
Retatrutide |
RT202605 |
WF03 |
2026-06-12 |
Pass |
Kovera |
View File |
|
|
CJC-1295 ND |
CJ202606 |
WF03 |
2026-06-09 |
Pass |
Kovera |
View File |
|
|
Retatrutide |
RT202607 |
WF03 |
2026-06-09 |
Pass |
Kovera |
View File |
|
|
Tirzepatide |
TZ202605 |
WF03 |
2026-06-09 |
Pass |
Kovera |
View File |
|
|
Epithalon |
ET202604 |
WF03 |
2026-05-14 |
Pass |
Kovera |
View File |
|
|
GHK-Cu |
CU202605 |
WF03 |
2026-05-29 |
Pass |
TrustPointe |
View File |
|
|
Epithalon |
ET202604 |
WF03 |
2026-05-14 |
Pass |
Kovera |
View File |
|
|
5-Amino-1MQ |
AM202604 |
WF03 |
2026-05-14 |
Pass |
Kovera |
View File |
|
|
Reconstitution Solution |
BAC202602 |
VI32 |
2026-05-14 |
Pass |
Kovera |
View File |
|
|
CJC-1295 ND / Ipamorelin |
CJIP202605 |
WF03 |
2026-05-14 |
Pass |
Kovera |
View File |
|
|
Cagrilintide |
CG202607 |
VI32 |
2026-05-14 |
Pass |
Kovera |
View File |
|
|
CIT: CJC-1295 ND / Ipamorelin / Tesamorelin |
CIT202604 |
WF03 |
2026-05-07 |
Pass |
Kovera |
View File |
|
|
DSIP |
DS202605 |
WF03 |
2026-05-07 |
Pass |
– |
Kovera |
View File |
|
BPC-157/TB-500 |
BB202605 |
VI32 |
2026-04-21 |
Pass |
Kovera |
View File |
|
|
Retatrutide |
RT202604 |
WF03 |
2026-04-22 |
Pass |
– |
Kovera |
View File |
|
KLOW Blend |
KW202604 |
WF03 |
2026-04-21 |
– |
Pass |
Kovera |
View File |
|
AOD-9604 |
AO202605 |
WF03 |
2026-04-20 |
– |
Pass |
Kovera |
View File |
|
Cagrilintide |
CG202603 |
VI32 |
2026-04-12 |
Pass |
– |
Kovera |
View File |
|
SS-31 |
SS202601 |
WF03 |
2026-04-12 |
– |
Pass |
Kovera |
View File |
|
MOTS-c |
MC202603 |
VI32 |
2026-04-04 |
Pass |
– |
Kovera |
View File |
|
Bacteriostatic Water |
BAC202601 |
WF03 |
2026-01-13 |
Pass |
– |
TrustPointe |
View File |
|
Bacteriostatic Water |
BAC20250807 |
SH07 |
2025-09-09 |
Pass |
– |
TrustPointe |
View File |
|
Meta-Z |
MZR20250713 |
DF05 |
2025-08-26 |
Pass |
– |
TrustPointe |
View File |
Verifiable certificates
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratory’s website shows that the certificate belongs to the supplier and the values haven’t been doctored. TrustPointe Analytics provides a few simple rules for verification:
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratory’s website shows that the certificate belongs to the supplier and the values haven’t been doctored. TrustPointe Analytics provides a few simple rules for verification:
Beware of fraudulent laboratories
Not only must one remain vigilant about potentially fraudulent certificates, one must also be aware that there are third-party laboratories whose results cannot be considered reliable or scientifically valid. Unfortunately, there is significant evidence to suggest that one of the most popular third-party testing labs does not use scientifically sound methodologies and, in some cases, has fabricated results. There isn’t an easy remedy for this problem, but when labs are particularly bad, there tend to be a lot of discussion threads on various social platforms.
Interpreting Endotoxin Results (via TrustPointe)
Our friends at TrustPointe have provided the following detailed explanation to help interpret the results of the endotoxin testing.
We use the Charles River Endosafe PTS system to test for bacterial endotoxins following USP <85> guidelines:
- USP <85> Bacterial Endotoxin Result:
Because it’s reported as “ - If a result is above the limit of detection of the cartridge, it will be reported as a number (without the “<“).
The following are suitability parameters that verify the system was working properly and the sample prep dilution is appropriate for accurate results. Peptides often interfere with endotoxin detection due to their tendency to bind or mask endotoxins, which can lead to inaccurate low results. To overcome this, samples are typically tested at a large dilution to reduce matrix interference and ensure reliable recovery and detection in compliance with USP <85>. If the dilution is not correct, the run will fail suitability and we’ll need to adjust the dilution to ensure accurate results. We provide the suitability data to customers for transparency and so they can be confident in the results.
USP <85> Sample CV %:
- CV stands for coefficient of variation, a measure of repeatability.
- For our lab, CV has to be <25% or the result to be considered valid
USP <85> Spike CV %:
- This refers to the precision of the positive control (spiked sample).
- Again, for our lab CV has to be <25% or the result to be considered valid
USP <85> Spike Recovery
- This tells us how much of the known endotoxin spike was recovered from your sample.
- The acceptable range is 50–200% per USP <85>
Related Products
- 5-Amino-1MQ (2 x 10mg vials)
- GLP-1 Semaglutide (20 x 10mg vials)
- GLP-1 Semaglutide (15 x 10mg vials)
Browse more in Metabolics.
Related products
